ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2022 16:04:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

06 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2022 16:16:00 By Nasdaq GlobeNewswire

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 May 2022 10:33:12 By Nasdaq GlobeNewswire

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 May 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 May 2022 16:01:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2022 08:00:04 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 Mar 2022 07:30:00 By Nasdaq GlobeNewswire